|
Vaccine Detail
L. donovani Recombinant LdγGCS in NIV system Vaccine |
Vaccine Information |
- Vaccine Name: L. donovani Recombinant LdγGCS in NIV system Vaccine
- Target Pathogen: Leishmania donovani
- Target Disease: Visceral leishmaniasis
- Vaccine Ontology ID: VO_0004241
- Type: Subunit vaccine
- Status: Research
- Antigen: Recombinant Leishmania donovani gamma-glutamyl cysteine synthetase protein (LdγGCS) (Henriquez et al., 2010).
- Adjuvant:
- Immunization Route: Intravenous injection (i.v.)
|
Host Response |
Mouse Response
- Host Strain: BALB/c
- Vaccination Protocol: The day of infection was day 0 so that vaccination occurred pre-infection on day −28 and day −14. Animals (n = 5/treatment) were immunized with either LPS (10 ng/ml equivalent to 5 EU/ml, 1 ng/dose), LdγGCS (2 or 50 µg, used as prepared or processed to remove endotoxin), or LdγGCS incorporated into NIV (50 µg) on days −28 and −14 (Henriquez et al., 2010).
- Challenge Protocol: On day 0 immunized mice and a control group (n = 4–10/treatment) were infected by intravenous injection (tail vein, no anaesthetic) with 1–2 × 10^7 L. donovani strain 200016 amastigotes harvested from the spleen of an infected hamster (Henriquez et al., 2010).
- Efficacy: Incorporating LdγGCS into a NIV formulation was more effective than immunization with LdγGCS alone based on its ability to induce specific antibody pre- and post-infection. However, the vesicular formulation gave a similar level of protection as immunization with LdγGCS alone (Henriquez et al., 2010).
|
References |
Henriquez et al., 2010: Henriquez FL, Campbell SA, Roberts CW, Mullen AB, Burchmore R, Carter KC. Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection. The Journal of parasitology. 2010; 96(5); 929-936. [PubMed: 20950100].
|
|